women-building-bio-2019-vabio-logo

Inova Center for Personalized Health, Fairfax You’re invited to spend the day with innovative entrepreneurs, professionals and industry leaders. Discover opportunities to help you navigate through a rapidly evolving modern industry & gain access to cutting edge technologies and tools.

Join forces with industry and academia leaders, researchers and decision-makers, all gathered together, at the same time, and at the same place, bringing ideas together to make a global impact and change the world.

Women Building Bio is where the future is transformed into reality.

drop-anywhere-labs-launch-party-logo

You are invited to join Learning Undefeated as we expand our reach again and welcome three new mobile laboratories.

Drop Anywhere Labs are the newest innovation in mobile STEM education, custom-built shipping containers that serve as flexible laboratory and classroom space for middle and high schools. Tour all six of our mobile laboratories including Drop Anywhere Labs, the Mobile eXploration Lab, MdBioLab, and Verizon explorer lab.

Event Info

Date: Thursday, August 1, 2019

Time: 4:00 - 6:00 PM

Alexandria-Real-Estate-Equities-Logo

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations, today announced that it has strategically partnered with Columbia University to open Alexandria LaunchLabs®, the premier life science startup platform, at the university in the spring of 2020. Building upon the success of the flagship Alexandria LaunchLabs site at the Alexandria Center® for Life Science – New York City, Alexandria LaunchLabs @ Columbia will increasingly focus on promising life science startups emerging from Columbia and peer institutions, which serve as the greatest source of new company formation in the NYC life science ecosystem.

lees-hopkins-almuni-award-image

Andrew Lees, Ph.D., is founder and scientific director of Fina Biosolutions, LLC (Rockville, Md.), a company focused on promoting affordable conjugate vaccines by making the technology available to emerging market vaccine manufacturers. Among his contributions in the field, Lees developed an efficient linking chemistry which is widely used in conjugate vaccines, a class that includes vaccines for S. pneumoniae and meningococcal disease. The chemistry has helped to reduce the cost of these vaccines.  

regenxbio-logo

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the first U.S. Food and Drug Administration (FDA) approval of a gene therapy that leverages REGENXBIO's proprietary NAV Technology Platform, Novartis AG's ZOLGENSMA® (onasemnogene abeparvovec-xioi; AVXS-101). ZOLGENSMA was approved by the FDA as a one-time infusion for pediatric patients with spinal muscular atrophy (SMA) who are less than two years of age.

hospital-doctor-stethascope-pixa

How does the healthcare sector stack up on gender equality? To answer that question, we look at pipeline practices, employee experiences, and policies and programs the industry has implemented to promote diversity and inclusion. We also hear from industry leaders on what it takes to accelerate change across the sector.

washington-dc-night-skyline-0523-pixa

A just-released study co-sponsored by the Biotechnology Innovation Organization (BIO) and AUTM provides new evidence of the significant contribution academic patent licensing makes to the U.S. economy. The report is the most recent in a series, and the numbers are astounding.

5-companies-bhcr.png

Gene therapies represent some of the most promising advancements in science and human health in recent history.  The BioHealth Capital Region, and Maryland in particular, is rapidly becoming a hub for companies in this field. With the NIH and the National Cancer Institute at the nucleus, some of the most advanced scientific research and technology development in the field is happening in a short 30-mile radius around Montgomery County, Maryland.

ceres-nano-logo

Ceres Nanosciences, Inc. (Ceres), University of Virginia (UVA), and George Mason University (Mason) today announced the receipt of a $600,000 award from the Virginia Catalyst for the development of a Nanotrap® liquid biopsy collection device. This award will be matched by $1.2 million in product development funding by Ceres Nanosciences.

brainbox-solutions-logo

BRAINBox Solutions today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's BRAINBox TBI (Traumatic Brain Injury) test in development, the first to aid in both the diagnosis and prognosis of mild TBI (concussion). The BRAINBox TBI test is a multi-modality, quantitative test that combines injury-related blood protein biomarkers with computerized neurological assessments.

body-parts-veins-organs-pixa

At the molecular level, we may not age gracefully; that is, we may not follow a continuous, linear downward slope. Instead, we may fall precipitously after we lose control of our exquisitely balanced anti-aging programs, sometime in our 50s. These findings, derived from a study of tissue-coding and noncoding RNA, may help explain why human disease burden increases so sharply from the sixth decade of life onward. They may also lead to therapies that enhance longevity, provided the natural termination of protective gene expression patterns does not indicate that they have outlived their usefulness.

maryland-logo

Whether you’re starting a business, relocating one, or just moving to live and work, there are endless reasons for why Maryland is the top state to relocate to. The BioHealth Capital Region continues to climb the GEN’s annual ranking of the nation’s top biopharma clusters, and was ranked fourth in 2018. There are many factors that make Maryland a great place to headquarter your BioHealth company. Biotech and life science companies are high-risk high expense ventures, and the location of your company is key to its success.

third-rock-ventures-logo

Biotechnology venture capital firm Third Rock Ventures has raised $770m for its fifth fund, a sign that investor interest in funding early-stage science continues unabated despite volatile public markets.

The investment vehicle, the largest ever raised by Third Rock in its 12-year history, will support investments in 10 to 12 companies. The Boston-based firm's new fund came together quickly.

vaccine-shot-pixa

For augmenting readability, The Research Insights has added a fresh market study, titled Vaccines Market to its flared database. The report has been put together in a chapter-wise arrangement, by separating required illustrations transversely. This report is an expedient tool to get responses to some of the queries that hold significance for the growth of the Vaccines Market during the forecast period. The evidence in the report was congregated from qualified organizations & dependable sources and was further authenticated by industry specialists for increased integrity

bio-new-logo

The Biotechnology Innovation Organization (BIO) released “Transforming Ideas into Advances: Best Practices in State and Regional Bioscience Economic Development Initiatives” today at the 2019 BIO International Convention.

The fifth edition of the Best Practices Guide is the bioscience industry’s leading comprehensive analysis of state legislative and regulatory initiatives in support of economic development.

sope-net-logo

Whether you have a medical device, diagnostic, health IT app, or therapeutic, if you have to obtain FDA approval to commercialize your product, you should attend this event! Learn about the obstacles, opportunities, draft guidances and new pathways you must consider when creating a regulatory strategy. In this ever-changing environment, the key to success is both transparency and a keen understanding of the options available for your regulatory pathway. 

June 19, 2019 6:00pm-8:30pm

Hood College, 401 Rosemont Avenue, Frederick, MD 21701

emergent-biosolution-logo

Emergent BioSolutions Inc. (EBS) today announced approval by the U.S. Food and Drug Administration (FDA) of the Prior Approval Supplement (PAS) submitted by the company for its oral cholera vaccine, Vaxchora® (Cholera Vaccine, Live, Oral). The PAS supports the change in storage conditions of the vaccine from frozen to refrigerated at 2-8°C and the transfer of bulk drug substance manufacturing from Emergent’s product development facility in San Diego to its manufacturing facility in Bern, Switzerland. The PAS also covers changes in labeling regarding these developments. The company’s oral cholera vaccine is the only FDA-licensed vaccine for the prevention of cholera caused by Vibrio cholerae serogroup O1, a potentially serious intestinal disease.

catalyze-bhi-release-logo-v2.jpg

Catalyze and BioHealth Innovation announce transatlantic partnership.

Amsterdam and Rockville, Maryland — Catalyze and BioHealth Innovation, Inc. have entered an agreement to actively bridge the Life Sciences communities in the US and the EU. This transatlantic partnership will increase opportunities for translating biohealth discoveries to market through grant writing services, expanded technology commercialization and international soft-landing support. The two parties have a wide range of resources and knowledge which combined will better aid in delivering high-impact, customer-specific solutions.